Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Comparing Decidual Inclusion vs. Exclusion in Uterine Suture Techniques During Cesarean Section to Improve Scar Thickness and Reduce Isthmocele Risk in Primiparous Women (DISSUC)

28. Mai 2026 aktualisiert von: Amr Sherif Hamza, Kantonsspital Baden

The Impact of Decidual Inclusion or Sparing in a Single Unlocked Closure of a Cesarean Uterine Incision: Randomized Controlled Trial

This study compares two ways of closing the uterus during cesarean delivery. In one group, the decidual layer near the uterine cavity is included in the suture. In the other group, this layer is left out. The study will examine whether these two methods differ in how well the uterine scar heals 6 to 9 months after surgery.

Women having an elective cesarean delivery will be randomly assigned to one of the two closure methods. Scar healing will be assessed by ultrasound after delivery. The goal is to determine whether one method is associated with better cesarean scar healing and fewer scar defects.

Studienübersicht

Detaillierte Beschreibung

Cesarean scar defects, also referred to as niches or isthmoceles, are associated with gynecologic symptoms and adverse outcomes in subsequent pregnancies. The effect of uterine closure technique on scar healing remains uncertain, particularly with regard to whether the cavum-near decidual layer should be included in or excluded from the suture during cesarean closure.

This study is a prospective, randomized, controlled trial comparing two approaches to single-layer, non-locked uterine closure during elective cesarean delivery: decidual inclusion and decidual sparing. In both study groups, all operative steps are standardized except for the handling of the cavum-near decidual layer at the uterotomy margin.

Participants will be followed 6 to 9 months after cesarean delivery, including blinded ultrasound assessment of cesarean scar healing. The objective is to determine whether decidual inclusion or decidual sparing is associated with differences in postoperative uterine scar healing and cesarean scar defect formation.

Studientyp

Interventionell

Einschreibung (Geschätzt)

374

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Amr S. Hamza, Assoc. Prof.
  • Telefonnummer: +41564863513
  • E-Mail: amr.hamza@ksb.ch

Studieren Sie die Kontaktsicherung

Studienorte

    • Canton of Aargau
      • Baden, Canton of Aargau, Schweiz, 5400
        • Kantonsspital Baden
        • Kontakt:
          • Amr S. Hamza, Assoc. Prof.
          • Telefonnummer: +41564863513
          • E-Mail: amr.hamza@ksb.ch
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Singleton, term pregnancy
  • Elective cesarean section before labor onset or membrane rupture
  • Maternal age >18 years
  • Ability to provide informed consent

Exclusion Criteria:

  • Placenta previa
  • Maternal substance abuse or infection
  • Suspected placenta accreta
  • Diabetes
  • one or more prior cesarean section
  • Vulnerable participants (e.g., mental health conditions)
  • Emergency cesarean sections

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Decidual Inclusion Closure
Participants randomized to this arm will undergo elective cesarean delivery with single-layer, non-locked uterine closure in which the cavum-near decidual layer at the uterotomy margin is included in the suture. All other operative steps will be performed according to the standardized study protocol.

During the cesarean section, the uterine incision is closed with a single-layered, non-locked suture. In this technique, the decidua (the uterine lining) is included in the closure. This means that the endometrial cells are part of the suture, potentially influencing the healing process of the uterine scar.

Goal: The idea is that including the decidua may promote better healing and scar formation, reducing the risk of complications such as isthmocele and improving long-term uterine health.

Experimental: Decidual Sparing Closure
Participants randomized to this arm will undergo elective cesarean delivery with single-layer, non-locked uterine closure in which the cavum-near decidual layer at the uterotomy margin is excluded from the suture. All other operative steps will be performed according to the standardized study protocol.

Procedure: In this technique, the uterine incision is also closed using a single-layered non-locked suture, but the decidua is excluded from the closure. The suture is placed only through the myometrium (muscle layer) of the uterus, leaving the decidua out of the scar tissue.

Goal: The intent is to observe if sparing the decidua results in better scar healing and a lower risk of isthmocele formation, as well as fewer long-term complications.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of participants with a cesarean scar niche measured by ultrasound
Zeitfenster: 6 to 9 months post-operation
Presence of a cesarean scar niche, defined as a myometrial indentation at the cesarean scar site with a depth of at least 2 mm, assessed by postoperative ultrasound. The outcome will be reported as the proportion of participants with a niche in each treatment group.
6 to 9 months post-operation

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Residual-to-adjacent myometrial thickness ratio
Zeitfenster: 6 to 9 months post-operation
Ratio of residual myometrial thickness to adjacent myometrial thickness measured by ultrasound.
6 to 9 months post-operation
Operative time
Zeitfenster: Periprocedural
Operative time in minutes
Periprocedural
Need for additional sutures for hemostasis
Zeitfenster: Periprocedural
Need for additional hemostatic sutures, yes (how many: __ Number) /no
Periprocedural
Length of hospital stay
Zeitfenster: Postoperative day 2
Length of postoperative hospital stay in days
Postoperative day 2
Postoperative pain intensity on the 11-point Numeric Rating Scale
Zeitfenster: Postoperative day 2
Pain intensity assessed using an 11-point Numeric Rating Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain.
Postoperative day 2
Postoperative bleeding
Zeitfenster: Postoperative day 2
Clinically relevant postoperative bleeding, yes/no
Postoperative day 2
Wound infection
Zeitfenster: Postoperative day 2
Postoperative wound infection, yes/no
Postoperative day 2
Postoperative fever
Zeitfenster: Postoperative day 2
Postoperative fever, yes/no
Postoperative day 2
Abnormal uterine bleeding
Zeitfenster: 6 to 9 months post-operation
Abnormal uterine bleeding reported at follow-up, yes/no
6 to 9 months post-operation
Dysmenorrhea
Zeitfenster: 6 to 9 months post-operation
Dysmenorrhea reported at follow-up, yes/no
6 to 9 months post-operation
Chronic pelvic pain
Zeitfenster: 6 to 9 months post-operation
Chronic pelvic pain reported at follow-up, yes/no
6 to 9 months post-operation
Dyspareunia
Zeitfenster: 6 to 9 months post-operation
Dyspareunia reported at follow-up, yes/no
6 to 9 months post-operation
Cesarean scar niche length measured by ultrasound in mm
Zeitfenster: 6 to 9 months post-operation
Length of cesarean scar niche in mm measured by ultrasound.
6 to 9 months post-operation
Cesarean scar niche depth measured by ultrasound in mm
Zeitfenster: 6 to 9 months post-operation
Depth of cesarean scar niche in mm measured by ultrasound.
6 to 9 months post-operation
Cesarean scar niche width measured by ultrasound in mm
Zeitfenster: 6 to 9 months post-operation
Width of cesarean scar niche in mm measured by ultrasound.
6 to 9 months post-operation
Residual myometrial thickness measured by ultrasound in mm
Zeitfenster: 6 to 9 months post-operation
Residual myometrial thickness measured by ultrasound in mm
6 to 9 months post-operation
Presence of intrauterine fluid on ultrasound
Zeitfenster: 6 to 9 months post-operation
Presence or absence of intrauterine fluid on ultrasound.
6 to 9 months post-operation

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Amr S. Hamza, Assoc. Prof., Kantonsspital Baden

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

25. Mai 2026

Primärer Abschluss (Geschätzt)

1. Mai 2029

Studienabschluss (Geschätzt)

30. Mai 2029

Studienanmeldedaten

Zuerst eingereicht

27. August 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. Mai 2026

Zuerst gepostet (Tatsächlich)

27. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

1. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

De-identified individual participant data will not be shared outside the research team because no external data-sharing process has been approved by the ethics committee or institution. Aggregate study results may be shared through publication or presentation.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren